Site-specific PEGylation at histidine tags

Bioconjugate Chemistry

Volumn 23, Issue 2, 2012, Pages 248-263

  Cong, Yuehua ^a   Pawlisz, Estera ^a   Bryant, Penny ^a   Balan, Sibu ^a   Laurine, Emmanuelle ^a   Tommasi, Rita ^a   Singh, Ruchi ^a   Dubey, Sitara ^a   Peciak, Karolina ^a   Bird, Matthew ^a   Sivasankar, Amrita ^a   Swierkosz, Julia ^a   Muroni, Maurizio ^a,c   Heidelberger, Sibylle ^c   Farys, Monika ^a   Khayrzad, Farzad ^a   Edwards, Jeff ^a   Badescu, George ^a   Hodgson, Ian ^b   Heise, Charles ^b   Somavarapu, Satyanarayana ^c   Liddell, John ^b   Powell, Keith ^a   Zloh, Mire ^c   Choi, Ji Won ^a   Godwin, Antony ^a   Brocchini, Steve ^a,c   more..

^a Antitope Ltd   (United Kingdom)

^b Fujifilm Diosynth Biotechnologies   (United Kingdom)

^c UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; BIOACTIVITY; CARDIOVASCULAR SYSTEM; SPECTROSCOPIC ANALYSIS;

BASED MEDICINES; CIRCULATION HALF-LIFES; CIRCULATORY SYSTEMS; HALF-LIFE OF PROTEIN; HIS-TAG; HISTIDINE TAGS; PEGYLATION; PROTEIN PEGYLATION; SITE-SPECIFIC; SPECIFIC CONJUGATIONS;

PROTEINS;

ALPHA2A INTERFERON; ANTIBODY; CYANOGEN BROMIDE; MACROGOL; METHIONINE; POLYHISTIDINE TAG;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHROMATOGRAPHY; CONJUGATION; CONTROLLED STUDY; COVALENT BOND; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STABILITY; RAT; STOICHIOMETRY;

EID: 84863155417     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc200530x     Document Type: Article

References (110)

1. Bailon, P. and Won, C. (2009) PEG-modified biopharmaceuticals Expert Opin. Drug Delivery 6 (1) 1-16
2. Jevsevar, S., Kunstelj, M. I., and Porekar, V. G. (2010) PEGylation of therapeutic proteins Biotechnol. J. 5 (1) 113-128
3. Kang, J., Deluca, P., and Lee, K. (2009) Emerging PEGylated drugs Expert Opin. Emerg. Drugs 14 (2) 363-380
4. Fishburn, C. (2008) The pharmacology of PEGylation: Balancing PD with PK to generate novel therapeutics J. Pharm. Sci. 97 (10) 4167-4183
5. Hamidi, M., Rafiei, P., and Azadi, A. (2008) Designing PEGylated therapeutic molecules: advantages in ADMET properties Expert Opin. Drug Dis. 3 (11) 1293-1307
6. Veronese, F. (2001) Peptide and protein PEGylation a review of problems and solutions Biomaterials 22 (5) 405-417 (Pubitemid 32007845)
7. Pisal, D. S., Kosloski, M. P., and Balu-Iyer, S. V. (2010) Delivery of therapeutic proteins J. Pharm. Sci. 99 (6) 2557-2575
8. Payne, R. W., Murphy, B. M., and Manning, M. C. (2010) Product development issues for PEGylated proteins Pharmaceutical Dev. Technol. 1-18
9. Marshall, S., Lazar, G., Chirino, A., and Desjarlais, J. (2003) Rational design and engineering of therapeutic proteins Drug Discovery Today 8 (5) 212-221 (Pubitemid 36298676)
10. Elliott, S., Lorenzini, T., Asher, S., Aoki, K., Brankow, D., Buck, L., Busse, L., Chang, D., Fuller, J., and Grant, J. (2003) Enhancement of therapeutic protein in vivo activities through glycoengineering Nat. Biotechnol. 21 (4) 414-421 (Pubitemid 36397662)
11. Sola, R. J. and Grievenow, K. (2010) Glycosylation of therapeutic proteins an effective strategy to optimize efficacy Biodrugs 24 (1) 9-21
12. Li, H. and D'anjou, M. (2009) Pharmacological significance of glycosylation in therapeutic proteins Curr. Opin. Biotechnol. 20 (6) 678-684
13. Andersen, J. and Sandlie, I. (2009) The versatile MHC class I-related FcRn protects IgG and albumin from degradation: Implications for development of new diagnostics and therapeutics Drug Metabol. Pharmacokinetics 24 (4) 318-332
14. Kim, H., Robinson, S., and Csaky, K. (2009) FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye Mol. Vis. 15, 2803-2812
15. Otagiri, M. and Chuang, V. (2009) Pharmaceutically important pre-and posttranslational modifications on human serum albumin Biol. Pharm. Bull. 32 (4) 527-534
16. Stork, R., Campigna, E., Robert, B., Muller, D., and Kontermann, R. E. (2009) Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives J. Biol. Chem. 284 (38) 25612-25619
17. Tuan Giam Chuang, V., Kragh-Hansen, U., and Otagiri, M. (2002) Pharmaceutical strategies utilizing recombinant human serum albumin Pharm. Res. 19 (5) 569-577 (Pubitemid 34553662)
18. Dennis, M., Zhang, M., Meng, Y., Kadkhodayan, M., Kirchhofer, D., Combs, D., and Damico, L. (2002) Albumin binding as a general strategy for improving the pharmacokinetics of proteins J. Biol. Chem. 277 (38) 35035-35043
19. Sung, C., Nardelli, B., Lafleur, D., Blatter, E., Corcoran, M., Olsen, H., Birse, C., Pickeral, O., Zhang, J., and Shah, D. (2003) An IFN-β-albumin fusion protein that displays improved pharmacokinetic and pharmacodynamic properties in nonhuman primates J. Interferon Cytokine Res. 23 (1) 25-36 (Pubitemid 36308059)
20. Halpern, W., Riccobene, T., Agostini, H., Baker, K., Stolow, D., Gu, M., Hirsch, J., Mahoney, A., Carrell, J., and Boyd, E. (2002) Albugranin TM, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic rffects in mice and monkeys Pharm. Res. 19 (11) 1720-1729 (Pubitemid 35305525)
21. Subramanian, G. M., Fiscella, M., Lamouseá-Smith, A., Zeuzem, S., and Mchutchison, J. G. (2007) Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C Nat. Biotechnol. 25 (12) 1411-1419 (Pubitemid 350233139)
22. Trussel, S., Dumelin, C., Frey, K., Villa, A., Buller, F., and Neri, D. (2009) New strategy for the extension of the serum half-life of antibody fragments Bioconjugate Chem. 20, 2286-2292
23. Foster, G. R. (2010) Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between Peginterferon α-2a and Peginterferon α-2b Drugs 70 (2) 147-165
24. Yang, B. (2006) Integration of pharmacokinetics and pharmcodynamics into the drug development of Pegfilgrastim, a PEGylated Protein, in Pharmacokinetics and Pharmacodynamics of Biotech Drugs (Meibohm, B., Ed.) pp 373-393, Wiley-VCH, Weinheim.
25. Grace, M., Lee, S., Bradshaw, S., Chapman, J., Spond, J., Cox, S., Delorenzo, M., Brassard, D., Wylie, D., Cannon-Carlson, S., Ccullen, Indelicato, S., Voloch, M., and Bordens, R. (2005) Site of pegylation and polyethylene glycol molecule size attenuate interferon-α antiviral and antiproliferative activities through the JAK/STAT signaling pathway J. Biol. Chem. 280 (8) 6327-6336 (Pubitemid 40341179)
26. Foser, S., Schacher, A., Weyer, K., Brugger, D., Dietel, E., Marti, S., and Schreitmullerc, T. (2003) Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon -2a (PEGASYS) Protein Expression Purif. 30, 78-87 (Pubitemid 36815235)
27. Pettit, D., Bonnert, T., Eisenman, J., Srinivasan, S., Paxton, R., Beers, C., Lynch, D., Miller, B., Yost, J., and Grabstein, K. (1997) Structure-function studies of interleukin-15 using site-specific mutagenesis, poly(ethylene glycol) conjugation, and homology modeling J. Biol. Chem. 272 (4) 2312
28. Dhalluin, C., Ross, A., Huber, W., Gerber, P., Brugger, D., Gsell, B., and Senn, H. (2005) Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha 2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2 Bioconjugate Chem. 16, 518-527 (Pubitemid 40696042)
29. Kubetzko, S., Sarkar, C., and Pluckthun, A. (2005) Protein PEGylation decreases observed target association rates via a dual blocking mechanism Mol. Pharmacol. 68, 1439-1454 (Pubitemid 41540000)
30. Shaunak, S., Godwin, A., Choi, J., Balan, S., Pedone, E., Vijayarangam, D., Heidelberger, S., Teo, I., Zloh, M., and Brocchini, S. (2006) Site-specific PEGylation of native disulfide bonds in therapeutic proteins Nat. Chem. Biol. 312-313 (Pubitemid 43787211)
31. Caliceti, P. and Veronese, F. (2003) Pharmacokinetic and biodistribution properties of poly (ethylene glycol)-protein conjugates Adv. Drug Delivery Rev. 55 (10) 1261-1277 (Pubitemid 37464561)
32. Hamidi, M., Azadi, A., and Rafiei, P. (2006) Pharmacokinetic consequences of Pegylation Drug Delivery 13 (6) 399-409 (Pubitemid 44470219)
33. Gonnelli, M. and Strambini, G. B. (2009) No effect of covalently linked poly (ethylene glycol) chains on protein internal dynamics Biochim. Biophpys. Acta 1794) 569-576
34. Rodriáguez-Martiánez, J., Solaá, R., Castillo, B., Cintroán-Coloán, H., Rivera-Rivera, I., Barletta, G., and Griebenow, K. (2008) Stabilization of α-chymotrypsin upon PEGylation correlates with reduced structural dynamics Biotechnol. Bioeng. 101 (6) 1142-1149
35. Lu, Y., Harding, S. E., Turner, A., Smith, B., and Athwal, D. S. (2008) Effect of PEGylation on the solution conformation of antibody fragments J. Pharm. Sci. 97 (6) 2062-2079
36. Youngster, S., Wang, Y. S., Grace, M., Bausch, J., Bordens, R., and Wyss, D. F. (2002) Structure, biology, and therapeutic implications of pegylated interferon alpha-2b Curr. Pharm. Des. 8 (24) 2139-2157 (Pubitemid 35203229)
37. Wang, Y., Youngster, S., Bausch, J., Zhang, R., Mcnemar, C., and Wyss, D. (2000) Identification of the major positional isomer of pegylated interferon alpha-2b Biochemistry 39, 10634-10640
38. Wang, Y., Youngster, S., Grace, M., Bausch, J., and Wyss, D. (2002) Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications Adv. Drug Delivery Rev. 54, 547-570 (Pubitemid 34618512)
39. Dhalluin, C., Ross, A., Leuthold, L., Foser, S., Gsell, B., Muller, F., and Senn, H. (2005) Structural and biophysical characterization of the 40 kDa PEG-interferon-a2a and its individual positional isomers Bioconjugate Chem. 16, 504-517 (Pubitemid 40696041)
40. Mancini, S., Amorotti, E., Vecchio, S., Ponz De Leon, M., and Roncucci, L. (2010) Infliximab-related hepatitis: discussion of a case and review of the literature Intern. Emerg. Med. 5 (3) 193-200
41. Giezen, T., Mantel-Teeuwisse, A., Straus, S., Schellekens, H., Leufkens, H., and Egberts, A. (2008) Safety-related regulatory actions for biologicals approved in the United States and the European Union J. Am. Med. Assoc. 300 (16) 1887-1896
42. Singh, S. K. (2011) Impact of product-related factors on immunogenicity of biotherapeutics J. Pharm. Sci. 100 (2) 354-387
43. Smolen, J., Landewe, R. B., Mease, P., Brzezicki, J., Mason, D., Luijtens, K., Van Vollenhoven, R. F., Kavanaugh, A., Schiff, M., Burmester, G. R., Strand, V., Vencovsky, J., and Van Der Heijde, D. (2009) Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial Ann. Rheum. Dis. 68 (6) 797-804
44. Balan, S., Choi, J., Godwin, A., Teo, I., Laborde, C., Heidelberger, S., Zloh, M., Shaunak, S., and Brocchini, S. (2007) Site-specific PEGylation of protein disulfide bonds using a three-carbon bridge Bioconjugate Chem. 18 (1) 61-76 (Pubitemid 46145995)
45. Woestenenk, E., Hammarström, M., Van Den Berg, S., Härd, T., and Berglund, H. (2004) His tag effect on solubility of human proteins produced in Escherichia coli: a comparison between four expression vectors J. Struct. Funct. Genomics 5 (3) 217-229 (Pubitemid 39030613)
46. Li, M. and Huang, D. (2007) On-column refolding purification and characterization of recombinant human interferon-λ1 produced in Escherichia coli Protein Expression Purif. 53 (1) 119-123 (Pubitemid 46283454)
47. Gaberc-Porekar, V. and Menart, V. (2005) Potential for using histidine tags in purification of proteins at large scale Chem. Eng. Technol. 28 (11) 1306-1314 (Pubitemid 41694143)
48. Arnau, J., Lauritzen, C., Petersen, G., and Pedersen, J. (2006) Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins Protein Expression Purif. 48 (1) 1-13 (Pubitemid 43782626)
49. Mayer, A., Francis, R. J., Sharma, S. K., Tolner, B., Springer, C. J., Martin, J., Boxer, G. M., Bell, J., Green, A. J., Hartley, J. A., Cruickshank, C., Wren, J., Chester, K. A., and Begent, R. H. J. (2006) A Phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug Clin. Cancer Res. 12 (21) 6509-6516 (Pubitemid 44799725)
50. Tolner, B., Smith, L., Hillyer, T., Bhatia, J., Beckett, P., Robson, L., Sharma, S., Griffin, N., Vervecken, W., and Contreras, R. (2007) From laboratory to Phase I/II cancer trials with recombinant biotherapeutics Eur. J. Cancer 43 (17) 2515-2522 (Pubitemid 350086936)
51. Murphy, R., Green, S., Ritter, G., Cohen, L., Ryan, D., Woods, W., Rubira, M., Cebon, J., Davis, I., Sjolander, A., Kypridis, A., Kalnins, H., Mcnamara, M., Moloney, M., Ackland, J., Cartwright, G., Rood, J., Dumsday, G., Healey, K., Maher, D., Maraskovsky, E., Chen, Y., Hoffman, E., Old, L., and Scott, A. (2005) Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions Prep. Biochem. Biotechnol. 35 (2) 119-134 (Pubitemid 40580631)
52. Kaslow, D. and Shiloach, J. (1994) Production, purification and immunogenicity of a malaria transmission-blocking vaccine candidate: TBV25H expressed in yeast and purified using nickel-NTA agarose Nat. Biotechnol. 12 (5) 494-499
53. Ward, E. S., Güssow, D., Griffiths, A. D., Jones, P. T., and Winter, G. (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli Nature 341 (6242) 544-546 (Pubitemid 19252529)
54. Gebauer, M. and Skerra, A. (2009) Engineered protein scaffolds as next-generation antibody therapeutics Curr. Opin. Chem. Biol. 13 (3) 245-255
55. Strohalm, M., Kavan, D., Novak, P., Volnyá, M., and Havlicek, V. (2010) mMass3: A cross-platform software environment for precise analysis of mass spectrometric data Anal. Chem. 82 (11) 4648-4651
56. Wittamer, V. (2003) The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency J. Biol. Chem. 279 (11) 9956-9962 (Pubitemid 38372597)
57. European Pharmacopeia. (2008) p 1110.
58. Lata, S. and Piehler, J. (2005) Stable and functional immobilization of histidine-tagged proteins via multivalent chelator headgroups on a molecular poly (ethylene glycol) brush Anal. Chem. 77 (4) 1096-1105 (Pubitemid 40261778)
59. Zaveckas, M., Žvirblienė, A., Žvirblis, G., Chmieliauskaitė, V., Bumelis, V., and Pesliakas, H. (2007) Effect of surface histidine mutations and their number on the partitioning and refolding of recombinant human granulocyte-colony stimulating factor (Cys17Ser) in aqueous two-phase systems containing chelated metal ions J. Chromatogr., B 852 (1-2) 409-419 (Pubitemid 46830134)
60. Bolanos-Garcia, V. and Davies, O. (2006) Structural analysis and classification of native proteins from E. coli commonly co-purified by immobilised metal affinity chromatography Biochim. Biophys. Acta 1760 (9) 1304-1313 (Pubitemid 44374210)
61. Kusterle, M., Jevševar, S., and Porekar, V. G. (2008) Size of Pegylated Protein Conjugates Studied by Various Methods Acta. Chem. Slov. 55, 594-601
62. Fee, C. (2007) Size comparison between proteins PEGylated with branched and linear poly (ethylene glycol) molecules Biotechnol. Bioeng. 98 (4) 725-731 (Pubitemid 350032676)
63. Veronese, F. M., Caliceti, P., and Schiavon, O. (1997) Branched and linear poly(ethylene glycol): Influence of the polymer structure on enzymological, pharmacokinetic, and immunological properties of protein conjugates J. Bioact. Compat. Polym. 12, 196-207 (Pubitemid 27470395)
64. Monfardini, C., Schiavon, O., Caliceti, P., Morpurgo, M., Harris, J. M., and Veronese, F. M. (1995) A branched monomethoxypoly (ethylene glycol) for protein modification Bioconjugate Chem. 6 (1) 62-69
65. Fee, C. J. and Van Alstine, J. M. (2004) Prediction of the viscosity radius and the size exclusion chromatography behavior of PEGylated proteins Bioconjugate Chem. 15 (6) 1304-1313 (Pubitemid 39552020)
66. Li, X., Shang, B., Wang, D., Zhang, S., Wu, S., and Y, A. (2011) Endostar, a modified recombinant human endostatin, exhibits synergistic effects with dexamethasone on angiogenesis and hepatoma growth Cancer Lett. 301, 212-220
67. Schellekens, H. (2002) Immunogenicity of therapeutic proteins: clinical implications and future prospects Clinical Therapeutics 24 (11) 1720-1740 (Pubitemid 35440946)
68. Veronese, F., Monfardini, C., and Caliceti, P. (1996) Improvement of pharmacokinetic, immunological and stability properties of asparaginase by conjugation to linear and branched monomethoxy poly(ethylene glycol) J. Controlled Release 40, 199-209 (Pubitemid 26238372)
69. Carrico, I. S. (2008) Chemoselective modification of proteins: hitting the target Chem. Soc. Rev. 37 (7) 1423-1431
70. Broyer, R. M., Grover, G. N., and Maynard, H. D. (2011) Emerging synthetic approaches for protein-polymer conjugations Chem. Commun. 47, 2212-2226
71. Ban, H., Gavrilyuk, J., and Barbas III, C. F. (2010) Tyrosine bioconjugation through aqueous ene-type reactions: A click-like reaction for tyrosine J. Am. Chem. Soc. 132 (5) 1523-1525
72. Minamihata, K., Goto, M., and Kamiya, N. (2011) Site-specific protein cross-linking by peroxidase-catalyzed activation of a tyrosine-containing peptide tag Bioconjugate Chem. 22, 74-81
73. Johnson, J. A., Lu, Y. Y., Van Deventer, J. A., and Tirrell, D. A. (2010) Residue-specific incorporation of non-canonical amino acids into proteins: recent developments and applications Curr. Opin. Chem. Biol. 14, 774-780
74. Liu, C. C. and Schultz, P. G. (2010) Adding new chemistries to the genetic code Annu. Rev. Biochem. 79, 413-444
75. Voloshchuk, N. and Montclare, J. K. (2009) Incorporation of unnatural amino acids for synthetic biology Mol. BioSyst. 6 (1) 65-80
76. Connor, R. E. and Tirrell, D. A. (2007) Non-canonical amino acids in protein polymer design Polym. Rev. 47 (1) 9-28
77. Wang, A., Winblade Nairn, N., Johnson, R. S., Tirrell, D. A., and Grabstein, K. (2008) Processing of N-terminal unnatural amino acids in recombinant human interferon-β inEscherichia coli ChemBioChem. 9 (2) 324-330 (Pubitemid 351196801)
78. Liao, J. (2007) Protein and cellular engineering with unnatural amino acids Biotechnol. Prog. 23 (1) 28-31 (Pubitemid 46293482)
79. Van Hest, J. (2007) Biosynthetic-synthetic polymer conjugates Polym. Rev. 47 (1) 63-92
80. Yang, K., Basu, A., Wang, M., Chintala, R., Hsieh, M., Liu, S., Hua, J., Zhang, Z., Zhou, J., Li, M., Phyu, H., Petti, G., Mendez, M., Janjua, H., Peng, P., Longley, C., Borowski, V., Mehlig, M., and Filpula, D. (2003) Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation Protein Eng. 16 (10) 761-770 (Pubitemid 37442447)
81. Rosendahl, M., Doherty, D., Smith, S., Carlson, S., Chlipala, E., and Cox, G. (2005) A long-acting, highly potent interferon -2 conjugate created using site-specific PEGylation Bioconjugate Chem. 16, 200-207 (Pubitemid 40129694)
82. Mei, B., Pan, C., Jiang, H., Tjandra, H., Strauss, J., Chen, Y., Liu, T., Zhang, X., Severs, J., Newgren, J., Chen, J., Gu, J., Subramanyam, B., Fournel, M. A., Pierce, G. F., and Murphy, J. E. (2010) Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment Blood. 116 (2) 270-279
83. Doherty, D. H., Rosendahl, M. S., Smith, D. J., Hughes, J. M., Chlipala, E. A., and Cox, G. N. (2005) Site-specific PEGylation of engineered cysteine analogues of recombinant human granulocyte-macrophage colony-stimulating factor Bioconjugate Chem. 16 (5) 1291-1298 (Pubitemid 41368133)
84. Filipovska, A. and Rackham, O. (2008) Building a parallel metabolism within the cell ACS Chem. Biol. 3 (1) 51-63 (Pubitemid 351227985)
85. Bloom, L. and Calabro, V. (2009) FN3: a new protein scaffold reaches the clinic Drug Discovery Today 14, 949-955
86. Lipovsek, D. (2011) Adnectins: engineered target-binding protein therapeutics Protein Eng. 24 (1-2) 3-9
87. Alley, S., Benjamin, D., Jeffrey, S., Okeley, N., Meyer, D., Sanderson, R., and Senter, P. (2008) Contribution of linker stability to the activities of anticancer immunoconjugates Bioconjugate Chem. 19, 759-765 (Pubitemid 351431408)
88. Gauthier, M. A. and Klok, H. A. (2011) Arginine-specific modification of proteins with poly(ethylene glycol) Biomacromolecules 12, 482-493
89. Sato, H. (2002) Enzymatic procedure for site-specific pegylation of proteins Adv. Drug Delivery Rev. 54, 487-504 (Pubitemid 34615545)
90. Maullu, C., Raimondo, D., Caboi, F., Giorgetti, A., Sergi, M., Valentini, M., Tonon, G., and Tramontano, A. (2009) Site-directed enzymatic PEGylation of the human granulocyte colony-stimulating factor FEBS J. 276 (22) 6741-6750
91. Rabuka, D. (2010) Chemoenzymatic methods for site-specific protein modification Curr. Opin. Chem. Biol. 14, 790-796
92. Defrees, S., Wang, Z. G., Xing, R., Scott, A. E., Wang, J., Zopf, D., Gouty, D. L., Sjoberg, E. R., Panneerselvam, K., Brinkman-Van Der Linden, E., Bayer, R. J., Tarp, M., and Clausen, H. (2006) GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli Glycobiology 16 (9) 833-843 (Pubitemid 44390927)
93. Plesner, B., Westh, P., and Nielsen, A. (2011) Biophysical characterisation of GlycoPEGylated recombinant human factor VIIa Int. J. Pharm. 406, 62-68
94. Stennicke, H. R., Østergaard, H., Bayer, R. J., Kalo, M. S., Kinealy, K., Holm, P. K., Sørensen, B. B., Zopf, D., and Bjørn, S. E. (2008) Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives Tierärztliche Praxis Großtiere 36 (3) 163-169
95. Henderson, G. E., Isett, K. D., and Gerngross, T. U. (2011) Site-specific modification of recombinant proteins: A novel platform for modifying glycoproteins expressed in E. coli Bioconjugate Chem. 22 (5) 903-912
96. Gault, V. A., Kerr, B. D., Irwin, N., and Flatt, P. R. (2008) C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes Biochem. Pharmacol. 75 (12) 2325-2333
97. Rajan, R. S., Li, T., Aras, M., Sloey, C., Sutherland, W., Arai, H., Briddell, R., Kinstler, O., Lueras, A. M. K., and Zhang, Y. (2006) Modulation of protein aggregation by polyethylene glycol conjugation: GCSF as a case study Protein Sci. 15 (5) 1063-1075
98. Basu, A., Yang, K., Wang, M., Liu, S., Chintala, R., Palm, T., Zhao, H., Peng, P., Wu, D., and Zhang, Z. (2006) Structure-function engineering of interferon-β-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation Bioconjugate Chem. 17 (3) 618-630 (Pubitemid 43794371)
99. Gaertner, H. F. and Offord, R. E. (1996) Site-specific attachment of functionalized poly (ethylene glycol) to the amino terminus of proteins Bioconjugate Chem. 7 (1) 38-44
100. Na, D. H., Lee, K. C., and Deluca, P. P. (2005) PEGylation of Octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics Pharm. Res. 22 (5) 743-749 (Pubitemid 40768586)
101. Nie, Y., Zhang, X., Wang, X., and Chen, J. (2006) Preparation and stability of N-terminal mono-PEGylated recombinant human endostatin Bioconjugate Chem. 17 (4) 995-999 (Pubitemid 44162618)
102. Lee, H., Jang, I. H., Ryu, S. H., and Park, T. G. (2003) N-terminal site-specific mono-PEGylation of epidermal growth factor Pharm. Res. 20 (5) 818-825 (Pubitemid 36515317)
103. Gilmore, J. M., Scheck, R. A., Esser-Kahn, A. P., Joshi, N. S., and Francis, M. B. (2006) N-Terminal protein modification through a biomimetic transamination reaction Angew. Chem., Int. Ed. 45 (32) 5307-5311 (Pubitemid 44289366)
104. Lee, B., Kwon, J., Kim, H., and Yamamoto, S. (2007) Solid-phase PEGylation of recombinant interferon α-2a for site-specific modification: process performance, characterization, and in vitro bioactivity Bioconjugate Chem. 18 (6) 1728-1734 (Pubitemid 350219969)
105. Kinstler, O., Molineux, G., Treuheit, M., Ladd, D., and Gegg, C. (2002) Mono-N-terminal poly(ethylene glycol)-protein conjugates Adv. Drug Delivery Rev. 54 (4) 477-485 (Pubitemid 34615544)
106. Wang, J., Hu, T., Liu, Y., Zhang, G., Ma, G., and Su, Z. (2011) Kinetic and stoichiometric analysis of the modification process for N-terminal PEGylation of staphylokinase Anal. Biochem. 412 (1) 114-116
107. Cindric, M., Cepo, T., Galic, N., Bukvic-Krajacic, M., Tomczyk, N., Vissers, J. P. C, Bindila, L., and Peter-Katalinic, J. (2007) Structural characterization of PEGylated rHu-GCSF and location of PEG attachment sites J Pharmaceut. Biomed. 44 (2) 388-395 (Pubitemid 46887640)
108. Zhai, Y., Zhao, Y., Lei, J., Su, Z., and Ma, G. (2009) Enhanced circulation half-life of site-specific PEGylated rh-GCSF: Optimization of PEG molecular weight J. Biotechnol. 14, 259-266
109. Tong, Y., Zhong, K., Tian, H., Gao, X., Xu, X., Yin, X., and Yao, W. (2010) Characterization of a mono PEG20000-Endostar Int. J. Biol. Macromol. 46 (3) 331-336
110. Block, H., Kubicek, J., Labahn, J., Roth, U., and Schäfer, F. (2008) Production and comprehensive quality control of recombinant human Interleukin-1β: A case study for a process development strategy Protein Expression Purif. 57, 244-254 (Pubitemid 350296974)